Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 05, 2023
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Journal: JAMA oncology
Published: November 03, 2022
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 20, 2021
Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone.
Journal: Journal of drugs in dermatology : JDD
Published: August 16, 2021
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.
Journal: Journal for immunotherapy of cancer
Published: January 20, 2019
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports.
Journal: Thyroid : official journal of the American Thyroid Association
Published: August 15, 2017
Melanoma brain metastasis: overview of current management and emerging targeted therapies.
Journal: Expert review of neurotherapeutics
Published: October 23, 2012
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
Journal: Journal of translational medicine
Published: October 29, 2009
Showing 1-8 of 8
Last Updated: 09/26/2026